Can Moolec avoid delisting? Nasdaq hearing set for December 18

Why is Moolec Science facing regulatory scrutiny over its annual 20-F filing with Nasdaq?

Moolec Science SA, listed on the Nasdaq under the ticker MLEC, has received a non-compliance determination from the Nasdaq Stock Market for failing to file its annual report on Form 20-F for the fiscal year ended June 30, 2025. The synthetic biology and molecular farming company disclosed that Nasdaq issued the letter on November 24, 2025, citing a breach of Listing Rule 5250(c)(1), which requires timely disclosure of periodic financial reports for continued listing eligibility.

The Luxembourg-based agri-biotech company, which develops genetically engineered crops that express animal protein analogues, stated that the delayed filing was the result of post-merger complexities following a business combination that closed in mid-June. This transaction introduced reverse acquisition accounting and required extensive revaluation of assets and liabilities under new financial reporting structures. As a result, the company was unable to complete its financial statements and associated audit procedures before the regulatory deadline.

To prevent immediate suspension, Moolec Science submitted a Form 12b-25 with the United States Securities and Exchange Commission on October 31, 2025, requesting additional time. The Nasdaq Hearings Panel subsequently granted a temporary stay of suspension, allowing Moolec’s shares to continue trading on the Nasdaq Capital Market while the company prepares for a compliance hearing scheduled for December 18, 2025. The company has indicated that it is working to complete the Form 20-F ahead of that date in order to regain full compliance.

How has Moolec’s mid-2025 business combination impacted its financial reporting timeline?

The business combination referenced by Moolec Science closed shortly before the end of its fiscal year and involved accounting for the transaction as a reverse acquisition. In such cases, the legal acquiree is considered the accounting acquirer, leading to significant adjustments in the company’s consolidated financials. This scenario often requires a full reassessment of historical financial records, valuation of both tangible and intangible assets, and the reconciliation of differing accounting standards across jurisdictions or corporate entities.

For a public company operating in the emerging molecular farming sector, where pre-commercial revenues and R&D-heavy balance sheets are typical, these adjustments can be particularly intricate. Moolec indicated that the delay was not due to underlying financial distress but rather the structural demands of integrating the business combination under revised accounting principles. Nevertheless, from a compliance standpoint, Nasdaq’s listing rules make no exceptions for procedural delays, and companies that miss annual filing deadlines are automatically flagged for review.

While such delays are not uncommon among small-cap firms undergoing rapid transformation, the visibility of a Nasdaq listing places pressure on management to address gaps in internal controls, reporting systems, and audit readiness. The non-compliance notice signals that Moolec Science will need to demonstrate to the panel not only its intent to comply, but a credible timeline backed by completed disclosures.

What risks do investors face ahead of Moolec’s December 18 hearing with Nasdaq?

For both institutional and retail investors, the most immediate risk is the potential suspension or delisting of Moolec Science’s shares from the Nasdaq Capital Market. While the stay granted by the Nasdaq Hearings Panel allows trading to continue for now, failure to file the overdue Form 20-F by the hearing date or to secure a favorable outcome at the hearing could result in the stock being delisted.

This would limit liquidity, reduce access to capital markets, and potentially trigger forced selling from funds with mandates that prohibit investment in over-the-counter securities. Beyond the structural implications, repeated compliance failures can also harm investor confidence, especially in sectors like foodtech and ag-biotech where visibility, governance, and access to funding are key differentiators.

Moolec Science is already on thin ice in this regard. In March 2025, the company was issued a separate non-compliance determination by Nasdaq after its share price fell below the $1.00 minimum bid requirement for more than 30 consecutive trading days. Under Listing Rule 5550(a)(2), the company was required to regain compliance by executing a reverse stock split or otherwise increasing its share price above the threshold. A compliance plan was submitted and a grace period was granted, but the company’s stock has remained volatile with limited trading volumes since.

In the context of this latest issue, analysts tracking the synthetic biology sector believe the company may face closer scrutiny during the hearing due to this pattern of repeated listing deficiencies, even if the underlying causes differ.

What does Moolec’s position in molecular farming mean for its longer-term viability?

Moolec Science operates at the frontier of alternative proteins and agricultural biotechnology, using a proprietary molecular farming approach that enables crops like soybeans and peas to produce animal-equivalent proteins within their cellular structures. This process allows the company to bypass fermentation bioreactors and instead rely on traditional farming infrastructure for large-scale protein production. The end goal is to develop sustainable, climate-aligned food ingredients that retain the functional benefits of animal-derived compounds.

The firm’s product pipeline spans multiple application areas including meat alternatives, dairy analogs, and nutritional oils. Moolec claims a growing patent portfolio of over 100 granted and pending filings, alongside operations in key agricultural markets across Latin America, the United States, and Europe.

Compared to other players in the alternative protein space that focus on precision fermentation or cell cultivation, Moolec’s strategy is differentiated by its reliance on agricultural scalability. However, this model also makes the company more dependent on crop cycles, regulatory approval for genetically modified traits, and the ability to secure partnerships with ingredient manufacturers and consumer goods firms.

Despite its potential, Moolec has yet to release any major commercial deals or revenue milestones since going public. The financial pressure of being a pre-revenue company, coupled with regulatory headwinds from multiple Nasdaq notices, has placed the spotlight squarely on whether the company can transition from an R&D-driven entity to a commercially viable operation.

What is the broader investor sentiment around Moolec Science and its Nasdaq compliance status?

Investor sentiment around Moolec Science remains cautious, with the stock underperforming in recent months and trading volumes thinning. While the company has not released updated financial guidance for fiscal 2026, market participants are closely watching the December 18 hearing as a critical inflection point for the company’s credibility and liquidity outlook.

The lack of sustained analyst coverage or institutional accumulation suggests that investor appetite may remain subdued until Moolec demonstrates improved financial reporting discipline, regulatory alignment, and operational momentum. Analysts following the foodtech and synthetic biology sectors note that public market access is becoming more difficult for early-stage, pre-commercial players, making Nasdaq compliance a baseline expectation rather than a value differentiator.

If Moolec can successfully file its Form 20-F and convince the panel to maintain its listing status, the stock could regain some investor confidence. However, any further delays or adverse decisions could have lasting consequences on its ability to raise capital, attract strategic partners, or execute future commercialization plans.

What are the key takeaways from Moolec Science’s Nasdaq compliance issue?

• Moolec Science SA received a non-compliance determination from the Nasdaq Stock Market for failing to file its annual Form 20-F for the fiscal year ended June 30, 2025.

• The delayed filing was attributed to post-closing complexities from a mid-June 2025 business combination involving reverse acquisition accounting and asset revaluation.

• Moolec submitted a Form 12b-25 on October 31, 2025, requesting additional time and a stay of suspension, which Nasdaq granted pending a hearing on December 18, 2025.

• This marks the second compliance issue for Moolec in 2025, following an earlier notice in March for falling below the $1.00 minimum bid requirement.

• Moolec’s shares continue to trade on the Nasdaq Capital Market under the ticker MLEC during the stay, but the risk of delisting remains if compliance is not achieved.

• Investors and analysts are closely watching whether Moolec can finalize its 20-F filing ahead of the hearing, as any further delay could affect its listing status and market confidence.

• Moolec operates in the emerging molecular farming sector, developing crops that produce animal protein analogues, but remains a pre-revenue firm with limited commercial traction.

• The hearing outcome will be a key inflection point for Moolec’s future viability as a publicly listed company and its ability to attract institutional support.